Abstract
Comparitive Study of Bupivacaine with Nalbuphine and Bupivacaine alone for Post-Operative Analgesia in Subarachnoid Block for Lower Limb Surgeries- Prospective Randomised Study
Highlights
Analgesia during post operative period is of main demand these days
Conclusion: we conclude that intrathecalnalbuphine at dosage of 1mg can be used as effective adjuvant along with 0.5% of hyperbaric bupivacaine intrathecally to have good post-operative analgesia
When nalbuphine is added as an adjuvant to intrathecal bupivacaine, it has potential to provide good intraoperative and post operative analgesia with decreased incidence of μ receptor side effectslike respiratory depression [4]
Summary
Analgesia during post operative period is of main demand these days. A pain free and stress free postoperative definitely helps in early mobilization and recovery. Intrathecal administration of opioids in conjunction with local anaesthetics improves the quality of intraoperative analgesia and provides superior quality and duration of analgesia post-operatively [1,2]. Nalbuphine is an opioid, which is structurally related to oxymorphone, highly lipid soluble with an agonist activity at kappa and an antagonist activity at μ opioid receptor [3]. When nalbuphine is added as an adjuvant to intrathecal bupivacaine, it has potential to provide good intraoperative and post operative analgesia with decreased incidence of μ receptor side effectslike respiratory depression [4]. Nalbuphine is a synthetic opioid , with kappa agonist or partial μ antagonist action. When added as an adjuvant to intrathecal bupivacaine, it acts on dorsal horn of spinal cord producing analgesia with decreased incidence of μ receptor side effects
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Anesthesia & Intensive Care Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
